Literature DB >> 23090840

Anti-N-methyl-D-aspartate receptor encephalitis with favorable outcome despite prolonged status epilepticus.

Xavier Finné Lenoir1, Christian Sindic, Vincent van Pesch, Souraya El Sankari, Marianne de Tourtchaninoff, Roger Denays, Philippe Hantson.   

Abstract

BACKGROUND: To describe a case of auto-immune encephalitis in an adolescent with favorable outcome despite prolonged status epilepticus.
METHODS: A 17 year old Asian man without previous medical history developed alteration of consciousness and partial seizures. The diagnosis of anti-N-methyl-D-aspartate receptor encephalitis was confirmed by the detection of specific antibodies in both cerebrospinal fluid and serum.
RESULTS: The clinical course was complicated by prolonged status epilepticus which was refractory to a large number of antiepileptic drugs, including barbiturate coma. Immunomodulatory therapy included steroids, plasma exchanges, and intravenous immunoglobulins. After 86 days of intensive therapy, the patient regained consciousness progressively. Brain magnetic resonance imaging never demonstrated any lesion. Extensive search for a tumor was negative. At 12 month follow-up, the patient had made an excellent recovery.
CONCLUSION: Auto-immune encephalitis is likely underdiagnosed in adolescents. In their most severe presentation, seizures may be resistant to a large number of anti-epileptic drugs, and the clinical improvement seems to be mainly because of the immunomodulatory therapy. Relapse is possible, as well as the delayed development of a teratoma or other tumor.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23090840     DOI: 10.1007/s12028-012-9788-8

Source DB:  PubMed          Journal:  Neurocrit Care        ISSN: 1541-6933            Impact factor:   3.210


  10 in total

Review 1.  Severe childhood encephalopathy with dyskinesia and prolonged cognitive disturbances: evidence for anti-N-methyl-D-aspartate receptor encephalitis.

Authors:  Claudia Poloni; Christian M Korff; Valeria Ricotti; Mary D King; Eliane Roulet Perez; Claire Mayor-Dubois; Charles-Antoine Haenggeli; Thierry Deonna
Journal:  Dev Med Child Neurol       Date:  2009-12-23       Impact factor: 5.449

2.  A subacute behavioral disorder in a female adolescent. Autoimmune anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma.

Authors:  André R De Nayer; Nathalie Myant; Christian J M Sindic
Journal:  Biol Psychiatry       Date:  2009-06-17       Impact factor: 13.382

3.  Ketamine successfully terminates malignant status epilepticus.

Authors:  Harald Prüss; Martin Holtkamp
Journal:  Epilepsy Res       Date:  2008-09-19       Impact factor: 3.045

4.  N-methyl-D-aspartate receptor autoimmune encephalitis presenting with opsoclonus-myoclonus: treatment response to plasmapheresis.

Authors:  Jonathan H Smith; Radhika Dhamija; Brian D Moseley; Paola Sandroni; Claudia F Lucchinetti; Vanda A Lennon; Orhun H Kantarci
Journal:  Arch Neurol       Date:  2011-08

Review 5.  Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis.

Authors:  Josep Dalmau; Eric Lancaster; Eugenia Martinez-Hernandez; Myrna R Rosenfeld; Rita Balice-Gordon
Journal:  Lancet Neurol       Date:  2011-01       Impact factor: 44.182

6.  Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma.

Authors:  Josep Dalmau; Erdem Tüzün; Hai-yan Wu; Jaime Masjuan; Jeffrey E Rossi; Alfredo Voloschin; Joachim M Baehring; Haruo Shimazaki; Reiji Koide; Dale King; Warren Mason; Lauren H Sansing; Marc A Dichter; Myrna R Rosenfeld; David R Lynch
Journal:  Ann Neurol       Date:  2007-01       Impact factor: 10.422

7.  Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies.

Authors:  Josep Dalmau; Amy J Gleichman; Ethan G Hughes; Jeffrey E Rossi; Xiaoyu Peng; Meizan Lai; Scott K Dessain; Myrna R Rosenfeld; Rita Balice-Gordon; David R Lynch
Journal:  Lancet Neurol       Date:  2008-10-11       Impact factor: 44.182

8.  Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents.

Authors:  Nicole R Florance; Rebecca L Davis; Christopher Lam; Christina Szperka; Lei Zhou; Saba Ahmad; Cynthia J Campen; Heather Moss; Nadja Peter; Amy J Gleichman; Carol A Glaser; David R Lynch; Myrna R Rosenfeld; Josep Dalmau
Journal:  Ann Neurol       Date:  2009-07       Impact factor: 10.422

9.  Diagnostic value of N-methyl-D-aspartate receptor antibodies in women with new-onset epilepsy.

Authors:  Pitt Niehusmann; Josep Dalmau; Christian Rudlowski; Angela Vincent; Christian E Elger; Jeffrey E Rossi; Christian G Bien
Journal:  Arch Neurol       Date:  2009-04

10.  Anti-N-methyl-D-aspartate receptor antibodies: a potentially treatable cause of encephalitis in the intensive care unit.

Authors:  Gerard Davies; Sarosh R Irani; Cordelia Coltart; Gordon Ingle; Yogen Amin; Christopher Taylor; Jeremy Radcliffe; Nicholas P Hirsch; Robin S Howard; Angela Vincent; Dimitri M Kullmann
Journal:  Crit Care Med       Date:  2010-02       Impact factor: 7.598

  10 in total
  4 in total

1.  Clinical characteristics and outcomes between children and adults with anti-N-Methyl-D-Aspartate receptor encephalitis.

Authors:  Qi Huang; Yuan Wu; Rongfa Qin; Xing Wei; Meigang Ma
Journal:  J Neurol       Date:  2016-09-15       Impact factor: 4.849

Review 2.  Treatment of Refractory and Super-refractory Status Epilepticus.

Authors:  Samhitha Rai; Frank W Drislane
Journal:  Neurotherapeutics       Date:  2018-07       Impact factor: 7.620

3.  A young child of anti-NMDA receptor encephalitis presenting with epilepsia partialis continua: the first pediatric case in Korea.

Authors:  Eun-Hee Kim; Yeo Jin Kim; Tae-Sung Ko; Mi-Sun Yum; Jun Hwa Lee
Journal:  Korean J Pediatr       Date:  2016-11-30

Review 4.  Anti-N-Methyl-D-aspartate Receptor Encephalitis: A Severe, Potentially Reversible Autoimmune Encephalitis.

Authors:  Cai-Yun Liu; Jie Zhu; Xiang-Yu Zheng; Chi Ma; Xu Wang
Journal:  Mediators Inflamm       Date:  2017-06-18       Impact factor: 4.711

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.